Leading the way
in PD-L1 testing

Introducing the first and only FDA-approved test to assess patients with NSCLC for KEYTRUDA® (pembrolizumab).

PD-L1 IHC 22C3 pharmDx

PD-L1 IHC 22C3 pharmDx leading the way in PD-L1 testing
PD-L1 IHC 22C3 pharmDx

Results you can trust

The first and only FDA-approved and
CE-IVD marked PD-L1 test for use in
non-squamous NSCLC for OPDIVO® (nivolumab).

PD-L1 IHC 28-8 pharmDx

PD-L1 IHC 28-8 pharmDx
PD-L1 IHC 28-8 pharmDx

PD-L1 IHC 28-8 pharmDx training

Learn how to evaluate PD-L1 expression in patients with non-squamous NSCLC for OPDIVO® (nivolumab).

PD-L1 IHC 28-8 pharmDx training

PD-L1 IHC 28-8 elearning
PD-L1 IHC 28-8
pharmDx training

Pathology Solutions

See our solutions within pathology, next generation sequencing and molecular cancer research.

Pathology Solutions

2016 Product Catalog

The 2016 Pathology Product Catalog is now available for download.

Download or order a copy

Events and Congresses

Meet us at congresses and events around the world.

List of future events

Country selection

Your Dako Account indicates that you are based in , you will be transfered to the web site for

Basket emptied

Your basket was emptied because of the country change.

Country selection

United States of America appears to be your location. To view country specific information on the Dako web site, please accept or change country below.


Dako Cookie Policy
This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. Privacy Statement



Get in Touch with Dako in Canada

Contact Us Directly

info.ca@dako.com
Toll free Ontario and Quebec: +1 800 668 4630
Toll free Other Provinces: +1 800 387 8257
+1 289 290 3953

Pathology Products, Flow Cytometry Products and Specific Proteins
Dako Canada ULC

6705 Millcreek Dr., Unit #5
Mississauga, Ontario L5N 5M4

Detailed contact information

Submit an Inquiry

How would you like us to follow up?


Your session expired

You have been logged out. Log in again to retrieve your Cart.